OncoMatch/Clinical Trials/NCT04803539
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC
Is NCT04803539 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including capecitabine and capecitabine + camrelizumab + apatinib for breast cancer.
Treatment: capecitabine · capecitabine + camrelizumab + apatinib — Circulating tumor DNA (ctDNA) has been demonstrated to be an effective prognostic marker in breast cancer. Various studies have shown that early TNBC breast cancer patients with positive ctDNA have high risk of cancer recurrence and worse prognosis. This study aimed to identify TNBC patients with positive ctDNA and initiate boost therapy in these high risk patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 wild-type (ER <=1%)
TNBC is defined as ER <=1%
Required: PR (PGR) wild-type (PR <=1%)
TNBC is defined as ... PR <=1%
Required: HER2 (ERBB2) wild-type (IHC=1, or IHC=2 and FISH negative)
HER2 receptor IHC=1, or IHC=2 and FISH negative
Disease stage
Required: Stage II, III
Excluded: Stage IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: adjuvant chemotherapy — adjuvant
Patient receives adjuvant chemotherapy according to the NCCN guidelines
Cannot have received: anti-PD-1/PD-L1 therapy
Patient has previously received any PD1/PDL1 blockage treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify